Pharma

Just a cool #JPM15 Bluebird Bio slide that shows its impressive scope

Bluebird Bio‘s work has been at the epicenter of gene therapy, working on a litany of fields […]

Bluebird Bio‘s work has been at the epicenter of gene therapy, working on a litany of fields that intersect with the work of the industry’s top firms. This slide from its J.P. Morgan presentation this week illustrates that quite nicely:

The company’s stock has just killed it in the past year – from $BLUE trading around $17 per share a year ago to hitting highs above $100 this year.

Biopharma Dive wrote of the #JPM15 presentation:

It’s one of the hottest biotechs in the world, and it’s planning on presenting major clinical data by the end of the year. bluebird bio CEO Nick Leschly told JPM15 attendees that the company will unveil data for its ambitious sickle cell gene therapy platform LentiGlobin in 2015.

Worth watching, if you haven’t, is CEO Nick Leschly’s TEDxBoston talk from a couple years ago.

Shares0
Shares0